Arthritis Research & Therapy

official impact factor 4.36
Search for
Advanced search
Arthritis Research & Therapy
Tools
Open Access

Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study

Jennie Ursum, Markus MJ Nielen, Dirkjan van Schaardenburg, Ann R van der Horst, Rob J van de Stadt, Ben AC Dijkmans and Dörte Hamann*

Arthritis Research & Therapy 2008, 10:R12 doi:10.1186/ar2362

Accesses  

  • Last 30 days: 45 accesses
  • Last year: 617 accesses
  • All time: 3889 accesses

Cited by

BioMed Central: 2 citations

Review   Free

The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis

Ger JM Pruijn, Allan Wiik, Walther J van Venrooij Arthritis Research & Therapy 2010, 12:203 (15 February 2010)

Abstract | Full text | PDF | PubMed

Research article   Open Access Highly Accessed

Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

Pascale Nicaise Roland, Sabine Grootenboer Mignot, Alessandra Bruns, Margarita Hurtado, Elisabeth Palazzo, Gilles Hayem, Philippe Dieudé, Olivier Meyer, Sylvie Chollet Martin Arthritis Research & Therapy 2008, 10:R142 (10 December 2008)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central | Editor’s summary

Antibodies to mutated citrullinated vimentin complement the use of anti-cyclic citrullinated peptides antibodies in the diagnosis of rheumatoid arthritis, and may be useful for monitoring infliximab therapy.

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations